# POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE (polyglyceryl-3-methylglucose-distearate) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/polyglyceryl-3-methylglucose-distearate
- **Standard INCI**: `POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE`
- **KR MFDS Standard Name**: `폴리글리세릴-3메틸글루코오스다이스테아레이트`
- **CAS No.**: `N/A`
- **EC / EINECS No.**: `N/A`
- **Origin**: `synthetic`
- **Functions**: 유화제
- **Molecular Formula / MW**: `—` (— g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 폴리글리세릴-3메틸글루코오스다이스테아레이트 |
| KR (Former Names) | 폴리글리세릴-3메칠글루코오스디스테아레이트 |
| EU (CosIng 1223/2009) | POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE |
| US (PCPC / MoCRA INCI) | POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | 聚甘油-3 甲基葡糖二硬脂酸酯 |
| JP (JCIA / MHLW QD) | POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `none`
- **EU (1223/2009)**: `none`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `allowed` (Entry: `3830`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- **cn_iecic_max** (leave_on): ≤ 6% — NMPA IECIC (2025) Entry 03628 (2025)
- **cn_iecic_max** (rinse_off): ≤ 5% — NMPA IECIC (2025) Entry 03628 (2025)

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 4.5 – 8.5
- **Max Process Temp**: ≤ 85°C
- **Synergy Pairings**: CETEARYL ALCOHOL, GLYCERYL STEARATE, SODIUM STEAROYL GLUTAMATE, CAPRYLIC/CAPRIC TRIGLYCERIDE
- **Incompatibilities**: Emulsification below 70°C may lead to incomplete liquid crystal formation and viscosity drift

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE | CAS No.: N/A | EC No.: N/A
  - Origin: SYNTHETIC | Functions: 
  - Physicochemical Profile: Formula      | MW /(Polymer/Complex) | /   | Ionic Nature: non-ionic | CosIng/MFDS 
  - Official Regional Label Names: US [POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE] · EU [POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE] · CN [聚甘油-3 甲基葡糖二硬脂酸酯] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - Methyl-D-glucopyranoside, ethers with 1,2,3-propanetriol homopolymer, octadecanoates (1:1:2)  (3 mol glycerol average molar ratio) Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver  performance and structural formulation stability.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 3830 (聚甘油-3 甲基葡糖二硬脂酸酯))
  - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment).
  - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 6.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 5.0%
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - [emulsion_cream] Typical range: 1.0 ~ 4.0% (Median 2.5%, Ref: Evonik TEGO Care 450 TDS & Formulation Library (n=195)) — PEG-free O/W primary lamellar emulsifier
  - [sun_color] Typical range: 1.0 ~ 4.0% (Median 2.0%, Ref: Evonik TEGO Care 450 Sunscreen Guide) — O/W sunscreen & tone-up cream emulsifier
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Oil Phase (Heat to 75~80°C)
  - Optimal pH Range: pH 4.5 ~ 8.5 | Max Process Temp: Max 85°C | Electrolyte Tolerance: HIGH
  - Incompatibility / Caution: Emulsification below 70°C may lead to incomplete liquid crystal formation and viscosity drift
  - Synergy Pairings: CETEARYL ALCOHOL, GLYCERYL STEARATE, SODIUM STEAROYL GLUTAMATE, CAPRYLIC/CAPRIC TRIGLYCERIDE | Reference Trade Names: TEGO® Care 450
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - PMID 29105631 (2017, Pak J Pharm Sci): Phytoformulation of Sassurea lappa plant extract: A Single blind, noninvasive and split face study of cream on various s
  - PMID 12058808 (2002, Farmaco): Influence of processing conditions in the manufacture of O/W creams: II. Effect on drug availability
  - PMID 12058807 (2002, Farmaco): Influence of processing conditions in the manufacture of O/W creams: I. Effect on dispersion grade and rheological chara

## 6. Linked PubMed Literature
- [PMID: 29105631] Phytoformulation of Sassurea lappa plant extract: A Single blind, noninvasive and split face study of cream on various skin parameters — *Pak J Pharm Sci* (2017)
- [PMID: 12058808] Influence of processing conditions in the manufacture of O/W creams: II. Effect on drug availability — *Farmaco* (2002)
- [PMID: 12058807] Influence of processing conditions in the manufacture of O/W creams: I. Effect on dispersion grade and rheological characteristics — *Farmaco* (2002)